Talk:AIM ImmunoTech: Difference between revisions
No edit summary |
|||
Line 4: | Line 4: | ||
{{WikiProject Pharmacology|class=Stub|importance=Low}} |
{{WikiProject Pharmacology|class=Stub|importance=Low}} |
||
{{WikiProject Companies|class=Stub|importance=Low}}}} |
{{WikiProject Companies|class=Stub|importance=Low}}}} |
||
Information on current page is not very informative or helpful. Paragraphs three and four had to do with complicated derivative accounting issues which occurred eleven years ago and is irrelevant. |
|||
Proposed text: |
|||
Hemispherx Biopharma, Inc. is a specialty pharmaceutical company headquartered in Philadelphia, Pennsylvania and engaged in the clinical development of new drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based disorders. Hemispherx first formed in 1966 and in the early 1970s was doing contract research for the National Institutes of Health. Since then, Hemispherx has established a strong foundation of laboratory, pre-clinical and clinical data with respect to the development of natural interferon and nucleic acids to enhance the natural antiviral defense system of the human body and to aid the development of therapeutic products for the treatment of certain chronic diseases. |
|||
Hemispherx’s flagship products include Alferon N Injection® and the experimental therapeutic Ampligen®. |
|||
Alferon N Injection® is approved in the United States for a category of STD infection, and Ampligen® represents an experimental RNA being developed for globally important viral diseases and disorders of the immune system. Hemispherx' platform technology includes components for potential treatment of various severely debilitating and life threatening diseases. Alferon® LDO (Low Dose Oral) is a formulation under development targeting influenza. |
|||
Alferon N Injection® has also received approval in Argentina (pending brand name “Naturaferon”) for use in any patients who fail or become intolerant to recombinant interferon, including patients with chronic active hepatitis C infection. |
|||
Ampligen® is in late stage clinical trials in the United States and has received approval from Administracion Nacional de Medicamentos, Alimentos y Tecnologia Medica (ANMAT) for commercial sale of rintatolimod (U.S. tradename: Ampligen®, proposed tradename for Argentina: Rintamod®) in the Argentine Republic for the treatment of severe myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). |
|||
GP Pharm Latinoamerica, an affiliate company of Spanish GP Pharm SA, is Hemispherx’s exclusive commercial partner for Ampligen and Alferon N Injection in Argentina and other possible Latin America countries. |
|||
Hemispherx has worldwide patents comprising its core intellectual property estate. |
|||
Hemispherx wholly owns and exclusively operates a GMP certified manufacturing facility in the United States for commercial products. |
|||
<ref>SEC filing on Form 10-K for Fiscal Year ended December 31,2017 http://ir.hemispherx.net/profiles/investor/secDL.asp?m=sv&c=946644&ID=000149315217003242/0001493152-17-003242</ref> |
|||
[[User:BluebirdHill5|BluebirdHill5]] ([[User talk:BluebirdHill5|talk]]) 21:55, 4 April 2017 (UTC){{coi}} Hemispherx Biopharma, Inc. |
Revision as of 21:55, 4 April 2017
This is the talk page for discussing improvements to the AIM ImmunoTech article. This is not a forum for general discussion of the article's subject. |
Article policies
|
Find sources: Google (books · news · scholar · free images · WP refs) · FENS · JSTOR · TWL |
This article has not yet been rated on Wikipedia's content assessment scale. It is of interest to the following WikiProjects: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Please add the quality rating to the {{WikiProject banner shell}} template instead of this project banner. See WP:PIQA for details.
Please add the quality rating to the {{WikiProject banner shell}} template instead of this project banner. See WP:PIQA for details.
Please add the quality rating to the {{WikiProject banner shell}} template instead of this project banner. See WP:PIQA for details.
Please add the quality rating to the {{WikiProject banner shell}} template instead of this project banner. See WP:PIQA for details.
|
Information on current page is not very informative or helpful. Paragraphs three and four had to do with complicated derivative accounting issues which occurred eleven years ago and is irrelevant.
Proposed text:
Hemispherx Biopharma, Inc. is a specialty pharmaceutical company headquartered in Philadelphia, Pennsylvania and engaged in the clinical development of new drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based disorders. Hemispherx first formed in 1966 and in the early 1970s was doing contract research for the National Institutes of Health. Since then, Hemispherx has established a strong foundation of laboratory, pre-clinical and clinical data with respect to the development of natural interferon and nucleic acids to enhance the natural antiviral defense system of the human body and to aid the development of therapeutic products for the treatment of certain chronic diseases.
Hemispherx’s flagship products include Alferon N Injection® and the experimental therapeutic Ampligen®.
Alferon N Injection® is approved in the United States for a category of STD infection, and Ampligen® represents an experimental RNA being developed for globally important viral diseases and disorders of the immune system. Hemispherx' platform technology includes components for potential treatment of various severely debilitating and life threatening diseases. Alferon® LDO (Low Dose Oral) is a formulation under development targeting influenza.
Alferon N Injection® has also received approval in Argentina (pending brand name “Naturaferon”) for use in any patients who fail or become intolerant to recombinant interferon, including patients with chronic active hepatitis C infection.
Ampligen® is in late stage clinical trials in the United States and has received approval from Administracion Nacional de Medicamentos, Alimentos y Tecnologia Medica (ANMAT) for commercial sale of rintatolimod (U.S. tradename: Ampligen®, proposed tradename for Argentina: Rintamod®) in the Argentine Republic for the treatment of severe myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS).
GP Pharm Latinoamerica, an affiliate company of Spanish GP Pharm SA, is Hemispherx’s exclusive commercial partner for Ampligen and Alferon N Injection in Argentina and other possible Latin America countries.
Hemispherx has worldwide patents comprising its core intellectual property estate.
Hemispherx wholly owns and exclusively operates a GMP certified manufacturing facility in the United States for commercial products.
BluebirdHill5 (talk) 21:55, 4 April 2017 (UTC)
A major contributor to this article appears to have a close connection with its subject. |
Hemispherx Biopharma, Inc.
- ^ SEC filing on Form 10-K for Fiscal Year ended December 31,2017 http://ir.hemispherx.net/profiles/investor/secDL.asp?m=sv&c=946644&ID=000149315217003242/0001493152-17-003242
- Stub-Class Pennsylvania articles
- Low-importance Pennsylvania articles
- Stub-Class Philadelphia articles
- Low-importance Philadelphia articles
- Stub-Class pharmacology articles
- Low-importance pharmacology articles
- WikiProject Pharmacology articles
- Stub-Class company articles
- Low-importance company articles
- WikiProject Companies articles